Apogee Therapeutics Inc. - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Representative image: AbbVie’s reported $10.9 billion Apogee Therapeutics acquisition talks highlight investor focus on zumilokibart, immunology pipeline expansion and the high-risk race to build growth beyond Humira.

Read More

Pharma Industry News

AbbVie weighs $10.9bn Apogee deal to strengthen its next immunology growth cycle

AbbVie may pay $10.9 billion for Apogee Therapeutics before Phase 3. Read what the reported deal could mean for immunology growth and ABBV stock.

June 22, 2026

web analytics